Tenderwize
Back to tender search

Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R))

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 193 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R))

15/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

15 / 100

Complexity

20 / 100

Risk factors

No estimated value, framework maximum, or lot values provided. Cannot estimate potential revenue.

Contract automatically ends upon patent expiry/loss of market exclusivity of Genvoya®. At that point, generic competiti...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of the pharmaceutical product Genvoya® (Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat) under discount agreements
  • Participation open to any pharmaceutical company that markets or intends to market Genvoya® in Germany
Show full summary

Open House procedure by Techniker Krankenkasse (TK) and other German health insurers to conclude discount agreements under §130c SGB V for the active ingredient combination Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya®). The procedure allows any eligible pharmaceutical company to join at any time during the 24-month contract period (01.03.2025 – 28.02.2027). No negotiation on terms; standard conditions apply. No exclusivity. The notice indicates this is not a public procurement subject to EU directives but published voluntarily. Value not disclosed.

Risks

No estimated value, framework maximum, or lot values provided. Cannot estimate potential revenue.

Contract automatically ends upon patent expiry/loss of market exclusivity of Genvoya®. At that point, generic competiti...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Participant must be a pharmaceutical entrepreneur as defined in §4(18) AMG with respect to the offered drug
  • Must have a valid marketing authorization for Genvoya® or be otherwise entitled to place it on the market in Germany
  • Seat must be in Germany, EU/EEA

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria – all eligible participants are accepted.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R))

Single lot covering discount agreements for the fixed-dose combination Genvoya®. Contract duration max 24 months starting 01.03.2025, ends automatically at patent expiry or earlier.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Feb 2025 - Feb 2027

Category

Pharmaceutical products

Award Criteria

No award criteria – all eligible participants are accepted.

Deadline

Deadline Feb 27, 2027

Procurement Details

Publication date
20 Jan 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
41398-2025

Documents (1)

Similar tenders